AzTrials
AzTrials

Epilepsies, PartialEPILOGNCT03882151

Added Value of Automated Electrical Source Localization (EPILOG PreOp®) to Presurgical Evaluation of Refractory Epilepsy

A study testing electrical source imaging in people with Epilepsies, Partial, run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain at 2 sites in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Drug resistant epilepsy is best managed by surgery. The goal of presurgical evalution is to correctly identify the epileptogenic zone, defined by the extent of cortical tissue that needs to be removed is order to achieve seizure freedom. Read more about this study

Who is it for?
Ages Up to 65 years
Conditions the study is for
Epilepsies, Partial
What is being tested?
electrical source imaging
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
2 sitesBelgium
Study dates
15 Jan 2019to 31 Dec 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 65 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • drug resistant epilepsy under presurgical evaluation
  • non lesional 3Tesla MRI scan
  • epileptic seizure(s) recorded during video-EEG monitoring

Who cannot join

  • patient does not agree for follow-up during 6 months
  • patient has an obvious causal lesion on MRI scan

Trial locations and contacts

2 sites in 1 country.

Susana Ferrao Santos, MD, PhD contact

027647801

susana.ferrao@uclouvain.be

Belgium2 sites, 2 recruiting
  • Saint-Luc University Hospital

    Brussels, 1200

    Susana Ferrao Santos, MD, PhD, 003227647801, susana.ferrao@uclouvain.be

    Recruiting
  • Centre Hospitalier William Lennox

    Ottignies, 1340

    Pascal Vrielynck, MD, 003210430338, pascal.vrielynck@chnwl.be

    Recruiting

Other trials in Belgium

About this study

Official title: What is the Added Clinical Value of an Automated EEG Analysis Program With Electrical Source Localization (EPILOG PreOp®) as Part of the Pre-surgical Assessment of Non-lesional Refractory Epilepsy?

Drug resistant epilepsy is best managed by surgery. The goal of presurgical evalution is to correctly identify the epileptogenic zone, defined by the extent of cortical tissue that needs to be removed is order to achieve seizure freedom. When no causative lesion is identified, careful study of interictal activity is mandatory. Complementary analysis methods exist, designed to identify the source of electrical activity recorded with surface electro-encephalogram. While results are interesting in retrospective studies, the real clinical added value needs to be demonstrated with prospective studies. The company Epilog (Epilog, Ghent, Belgium) offers, with EPILOG PreOp®, a long-term EEG analysis to automatically detect epileptiform activity, combined with an estimation of the electrical source localization using a sLORETA inverse solution model. We will propose the EPILOG PreOp analysis to refractory epileptic patients with non-contributive cerebral imaging, under presurgical evaluation. By comparing the therapeutic decision with and without knowledge of the results of EPILOG PreOp®, we will establish the added clinical value of EPILOG PreOp®.

Read the detailed description

Saint-Luc University Hospital (CUSL) are the sponsor of the study. The study is bi-centric, in collaboration with the William Lennox Neurological Hospital Center (CHNWL).

Will be included prospectively the first thirty patients with refractory focal epilepsy being evaluated at CUSL or CHNWL between for surgery, and for whom the cerebral MRI 3 Tesla (3T) did not show any obvious causal lesion.

The pre-surgical evaluation includes (standard of care - SOC):

  • EEG-video scalp monitoring (SOC)
  • MRI 3Tesla (SOC)
  • PET scan FDG (SOC)
  • neuropsychological assessment (SOC) MRI examination will be reviewed by an experienced neuroradiologist at CUSL (SOC).

The automated EEG analysis and electrical source localization with EPILOG PreOp® (non-SOC) will be carried out by Epilog (Epilog, Ghent, Belgium), blind to the rest of the workup. The costs of this analysis are 250 € / patient and will be covered by a clinical research fund. If the patient is referred by the CUSL, the costs are charged to account 830 E. If the patient is referred by the CHNWL, the costs are charged to a local scientific account.

The results of the pre-surgical evaluation will be discussed in a multidisciplinary meeting, blind to the results of EPILOG PreOp®, in order to determine the presumed localization of the epileptogenic zone as well as the management plan. The result of this discussion will be classified as follows:

  • A focal surgical resection is possible;
  • B the assessment must be completed by an invasive EEG (SOC);
  • C the option of resective surgery is rejected. If an invasive EEG is considered, the anatomical location of electrodes is planned. Then, the results of EPILOG PreOp® are presented (by Dr. Susana Ferrao Santos) and their influence on the management is evaluated. The possible change of care in relation to the initial plan is considered to be relevant if the EPILOG PreOp® analysis results in
  1. a modification of the therapeutic decision as defined above,
  2. a modification of the invasive EEG implantation plan or
  3. the use of an additional non-invasive imaging method to delineate the epileptogenic zone or to establish the functional risk.

Patients will then be followed for 6 months to determine the clinical relevance of any management changes derived from the EPILOG PreOp® analysis. We will also evaluate the relationship between the localization of the EPILOG + regions (ie the brain regions involved in the irritative zone according to the results provided by the EPILOG PreOp® analysis), the surgical resection, the pathology analysis results and post-surgical results.

EPILOG PreOp® analysis will be carried out using the full length EEG recording collected during video-EEG monitoring (SOC) at CUSL or CHNWL, ie 7 days of recording. with 19-27 electrodes placed according to the international 10-20 system. The EEG data will be transmitted after acquisition and anonymization. For patients investigated at CHNWL, a high-density (non-SOC) recording with 64-76 electrodes will be offered for 24 to 48 hours if the investigator deems it necessary. The additional costs associated with high density EEG are borne by the CHNWL. The result will also be sent to Epilog for analysis, after anonymisation of the data.

The EPILOG PreOp® analysis will begin with automated detection of interictal epileptiform activity using the Persyst program (Persyst Spike Detector P13, Persyst, San Diego, CA, USA), and interictal activity will be clustered and localized. source will be estimated using the sLORETA inverse solution model, using the methodology described previously.

Pathology For all patients undergoing resective surgery, histological sections will be reviewed (SOC). Focal cortical dysplasias will be classified according to the ILAE (SOC) classification. Non-contributory results include: gliosis, absence of microscopic or histological abnormality.

Being tested
electrical source imaging
Keywords
epilepsy, drug resistant epilepsy, electrical source imaging, surgery
Medical subject headings
Epilepsies, Partial, Epilepsy, Drug Resistant Epilepsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • electrical source imagingDiagnostic test

    automated analysis of surface EEG with electrocal source imaging

Study groups in NCT03882151
Study groupRoleWhat they receive
Epilog PreopExperimentalpatients receive Epilog preop analysis
Receives: Diagnostic Test: electrical source imaging

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quantification of Epilog+ driven changes of management plan

    Descriptive analysis of population with results from Epilog Preop analysis that changed initial clinical decision (total number of patients, type management plan modification)

    Measured: up to 6 months after recruitment

Secondary outcomes (3)
  1. Sensitivity and specificity of Epilog+ compared to resection zone

    Are Epilog+ results in the same location as the resection zone?

    Measured: up to 24 months after recruitment

  2. Sensitivity and specificity of Epilog+ compared to pathology

    Are Epilog+ results identifying abnormal cortex?

    Measured: up to 24 months after recruitment

  3. Sensitivity and specificity of Epilog+ compared to seizure outcome

    What proportion of patients are seizure free if Epilog+ results are resected; what proportion of patients are not seizure free if Epilog + results are not resected?

    Measured: up to 24 months after recruitment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Mar 2019
  2. Study start15 Jan 2019
  3. Primary completion1 Jun 2020 (estimated)
  4. Study completion31 Dec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
All patients included will have Epilog Preop analysis
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03882151
Sponsor's protocol ID
2018/26SEP/355
Acronym
EPILOG
Status last verified
Mar 2019
First submitted
6 Mar 2019
Last updated
20 Mar 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing electrical source imaging in people with Epilepsies, Partial, run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain at 2 sites in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Susana Ferrao Santos, MD, PhD (027647801, susana.ferrao@uclouvain.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quantification of Epilog+ driven changes of management plan (time frame: up to 6 months after recruitment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in